Paclitaxel is a novel anticancer drug that has demonstrated efficacy toward
treating several malignant tumor types. Here, we demonstrate that c-Jun NH
2-terminal kinase (JNK), but not p38 mitogen-activated protein kinase or ex
tracellular signal-regulated kinase 1/2, was persistently activated by pacl
itaxel or other microtubule-damaging agents within human leukemia HL-60 cel
ls. Overexpression of a dominant-negative mutant, mitogen-activated protein
kinase kinase 1 (MEKK1-DN) or treatment with JNK-specific antisense oligon
ucleotide prevented paclitaxel-induced JNK activation, Bcl-2 phosphorylatio
n and apoptosis. Furthermore, we found that the full-length MEKK1 was cleav
ed to a 91-kDa carboxyl-terminal fragment at the earlier time of apoptosis
induced by microtubule-damaging agents. This cleavage, however, occurred co
nsistently with JNK activation and Bcl-2 phosphorylation, but preceded DNA
fragmentation in cells in response to paclitaxel activity. The caspase inhi
bitor Ac-Asp-Glu-Val-Asp-CHO (DEVD-CHO), but not Ac-Tyr-Val-Ala-Asp-CHO (Ac
-YVAD-CHO), effectively blocked MEKK1 cleavage, JNK activation, Bcl-2 phosp
horylation, and subsequent apoptosis. Subcellular fractionation revealed th
at the 91-kDa C-terminal MEKK1 fragment was translocated to cytosol. Notabl
y, the MEKK1 fragment could be coimmunoprecipitated with anti-JNK antibodie
s, suggesting that a signaling complex of C-terminal MEKK1/stress-activated
protein kinase/extracellular-signal regulated kinase 1/JNK formed during a
poptosis induced by microtubule-damaging agents. Taken together, our result
s suggest that disruption of cytoarchitecture by paclitaxel triggers a nove
l apoptosis-signaling pathway, wherein an active DEVD-directed caspase (DEV
Dase) initially cleaves MEKK1to generate a proapoptotic kinase fragment tha
t is able to activate JNK and subsequent Bcl-2 phosphorylation, finally eli
citing cell death.